Nebenwirkungen · Hyrimoz
Hyrimoz 20 mg solution for injection in pre-filled syringe Hyrimoz 40 mg solution for injection in pre-filled syringe Hyrimoz 40 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 23
HOS-137756 · Präparat HOS-098091
In post-marketing experience from January 2003 to December 2010, predominantly in patients with rheumatoid arthritis, the spontaneously reported rate of malignancies is approximately 2.7 per 1 000 patient treatment years. The spontaneously reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 per 1 000 patient treatment years, respectively (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-13T10:00:00Z · SHA-256 bb2e47f3048e41368975094658eb6e77cdd9bd77fdb14fd3af35a8737fa4ae2c · Passage 4165c4fa797921f8fc595ec73221170ee2ebf6a5ead19ef4b818783f9a0029cd · Zeichen 19553–19948 im Abschnitt